Protein kinase C -activating isophthalate derivatives mitigate Alzheimer's disease-related cellular alterations.

Abnormal protein kinase C (PKC) function contributes to many pathophysiological processes relevant for Alzheimer's disease (AD), such as amyloid precursor protein (APP) processing. Phorbol esters and other PKC activators have been demonstrated to enhance the secretion of soluble APPα (sAPPα), reduce the levels of ß-amyloid (Aß), induce synaptogenesis, and promote neuroprotection. We have previously described isophthalate derivatives as a structurally simple family of PKC activators. Here, we characterised the effects of isophthalate derivatives HMI-1a3 and HMI-1b11 on neuronal viability, neuroinflammatory response, processing of APP and dendritic spine density and morphology in in vitro. HMI-1a3 increased the viability of embryonic primary cortical neurons and decreased the production of the pro-inflammatory mediator TNFα, but not that of nitric oxide, in mouse neuron-BV2 microglia co-cultures upon LPS- and IFN-γ-induced neuroinflammation. Furthermore, both HMI-1a3 and HMI-1b11 increased the levels of sAPPα relative to total sAPP and the ratio of Aß42/Aß40 in human SH-SY5Y neuroblastoma cells. Finally, bryostatin-1, but not HMI-1a3, increased the number of mushroom spines in proportion to total spine density in mature mouse hippocampal neuron cultures. These results suggest that the PKC activator HMI-1a3 exerts neuroprotective functions in the in vitro models relevant for AD by reducing the production of TNFα and increasing the secretion of neuroprotective sAPPα.

Carcinogenicity of the drinking water mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone in the rat.

BACKGROUND: Several epidemiologic studies have suggested that the consumption of chlorinated drinking water may be associated with the development of certain cancers in humans. 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a byproduct of the chemical reactions that occur in chlorinated drinking water, has been found to be mutagenic in bacteria and mammalian cells; however, its potential to cause tumors in animals has not been tested previously. PURPOSE: The objective of this study was to evaluate the carcinogenicity of MX in rats given MX in their drinking water. METHODS: MX was administered to male and female Wistar rats (50 rats per dose group) in drinking water for 104 weeks at concentrations yielding the average daily doses of MX of 0.4 mg/kg of animal weight (low dose), 1.3 mg/kg (mid dose), and 5.0 mg/kg (high dose) for males and 0.6 mg/kg, 1.9 mg/kg, and 6.6 mg/kg for females, respectively. Control rats received water from the same source used for preparation of the MX dose formulations (after its adjustment to the same pH range). Body weight, clinical signs, and food and water consumption were recorded regularly. At the end of the treatment period, the animals were killed and full histopathologic analysis was performed on 47 tissues and all lesions. RESULTS: Dose-dependent increases in tumor incidence were observed in rats given MX-containing drinking water; the same MX doses had no obvious toxic effects on animals. MX consumption increased most drastically the prevalence of follicular adenoma (up to 43% and 72% in high-dose males and females, a test [one-sided] for positive trend in all dose groups P = .0045 and P = .0000, respectively) and carcinoma (55% [P = .0000] and 44% [P = .0000], respectively) in thyroid glands and cholangioma in the liver (8% [P = .0009] and 66% [P = .0000] in the high-dose males and females, respectively). Among rats given the higher doses of MX in their drinking water, cortical adenomas of the adrenal glands were increased in both sexes, alveolar and bronchiolar adenomas of the lungs and Langerhans' cell adenomas of the pancreas were increased in males, and lymphomas, leukemias, and adenocarcinomas and fibroadenomas of the mammary glands were increased in females. Even the lowest MX dose studied was carcinogenic. CONCLUSION: MX is a potent carcinogen in both male and female rats, and it causes tumors at doses that are not overtly toxic to rats. IMPLICATIONS: Although these findings cannot be extrapolated to humans, MX should be studied as a candidate risk factor in the possible association between consumption of chlorinated drinking water and cancer in humans.

Labelling, molecular modelling and biological evaluation of vardenafil: a potential agent for diagnostic evaluation of erectile dysfunction.

99mTc-tricarbonyl-vardenafil was specifically radiosynthesized for diagnostic evaluation of erectile dysfunction with a radiochemical yield ~97.2%. It was stable in saline up to 15h and in serum for more than 6h. The radiocomplex was lipophilic with a partition coefficient ~1.32 and plasma protein binding 72-76%. Its structure was determined using molecular mechanics and confirmed by NMR. In-silico docking to its target PDE5 enzyme was performed. The radiocomplex inhibitory activity was assessed and its IC50 was 0.7nM. Biodistribution in normal rats and biological evaluation in rat models of erectile dysfunction were performed. The results strongly suggested that 99mTc-tricarbonyl-vardenafil is a good candidate to image erectile dysfunction in humans.

Stimulation of adrenal medullary cells in vivo and in vitro induces expression of c-fos proto-oncogene.

The nuclear proto-oncogene, c-fos, has been implicated in the coordinated regulation of gene expression during cell proliferation and differentiation. In this study, we have demonstrated the induction of the c-fos gene products in differentiated cells of the adrenal medulla by non-mitogenic signals. Activation of adrenal medullary cells in vivo by insulin-induced hypoglycemia, and in vitro by nicotine or angiotensin resulted in the rapid and transient elevation of c-fos mRNA levels. Induction of the c-fos mRNA by angiotensin and nicotine were accompanied by the appearance of the c-fos protein. The increase in c-fos protein occurred initially in the cytoplasm and, later, in the nucleus, and it was co-localized with tyrosine hydroxylase. Nuclear expression of the c-fos protein was also induced by veratridine, forskolin and the calcium ionophore A231287. The role of calcium in the regulation of the c-fos gene by angiotensin with nifedipine and inhibition of the effects of angiotensin with nifedipine and sphingosine, a protein kinase C inhibitor. Activation of the c-fos gene may play a role in the coordinated induction of genes involved in the long-term adaptation of adrenal medullary cells to increased functional demands.

Role of protein kinase C in microglia-induced neurotoxicity in mesencephalic cultures.

Microglial activation selectively kills certain neuron populations in mixed neuronal/glial cultures, which may prove useful for modeling neurodegenerative diseases such as Parkinson's disease. In mesencephalic mixed neuronal/glial cultures, microglial activation by zymosan A killed more dopaminergic neurons, assessed by [3H]dopamine uptake and by counting tyrosine hydroxylase-immunoreactive neuron number, than did microglial activation by lipopolysaccharide (LPS). The additional toxicity of zymosan resulted from microglial protein kinase C (PKC) activation. Both zymosan and PMA, but not LPS, activated PKC in enriched microglial preparations. In the mixed neuronal/glial cultures, activation of PKC by phorbol myristate acetate (PMA) increased LPS-induced nitric oxide (NO; by nitrite measurements), but not zymosan-induced NO production, and increased LPS-induced dopaminergic neurotoxicity, but not zymosan-induced dopaminergic neurotoxicity. Additive effects of PMA and LPS, similar to zymosan effects alone, reflected activation of distinct neurotoxic pathways in the microglia. The NO synthase inhibitor N-nitro-L-arginine methyl ester (NAME) totally blocked the neurotoxicity of LPS, and partially blocked zymosan-induced neurotoxicity; NAME did not block the PKC component of neurotoxicity. In addition to stimulating NO production as effectively as LPS, zymosan also activates microglial PKC and associated non-NO-mediated neurotoxic pathways that may be important in human neurodegenerative diseases. Since the role of NO in human microglia-induced neurotoxicity is controversial, zymosan may prove more useful than LPS as a microglial activator in the rodent mixed neuronal/glial culture model.

Development of tolerance to the hormonal effects of morphine without changes in the aminergic functions in the brain of the rat.

The effect of morphine on cold-stimulated secretion of TSH and prolactin was studied in male rats, both in acute studies and after the chronic administration of morphine for 14 days (twice a day with increasing doses). The duration of the stimulatory effect of a single dose of morphine on secretion of prolactin was shorter (less than 2 hr) than its inhibitory effect on cold-stimulated secretion of TSH (over 2 hr). In the rats pretreated with morphine, a tolerance to the depressant effect of TSH of the challenge dose of morphine was seen at 2 hr but not at 1 hr after the injection. In contrast, a tolerance to the stimulatory effect of morphine on prolactin was seen at 1 hr after the acute dose of morphine. The minor alterations of the hypothalamic amine neurotransmitters and their metabolites did not correlate with the hormonal responses or to the development of tolerance.

Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.

1. We compared three new catechol O-methyltransferase (COMT) inhibitors (OR-611, Ro 40-7592 and CGP 28014; 10 and 30 mg kg-1, i.p.) in male rats given levodopa (L-DOPA, 50 mg kg-1, i.p.) and carbidopa ((-)-L-alpha-methyl dopa, 50 mg kg-1, i.p.). In some studies pretreatment with pargyline (80 mg kg-1, i.p.) was used to block the function of monoamine oxidase (MAO). 2. Decreases of hypothalamic and striatal 3-O-methyl-dopa (3-OMD) levels were used as measures of the inhibition of peripheral COMT. The inhibition of brain COMT activity was estimated by decreases of hypothalamic and striatal homovanillic acid (HVA) and 3-methoxytyramine (3-MT; after pargyline) levels. 3. The three COMT inhibitors studied had different individual characteristics. OR-611 was primarily a peripherally acting COMT inhibitor, decreasing 3-OMD levels in the striatum (to 31-52%) and in the hypothalamus (to 16-27%) both in the control and pargyline-treated animals at 1 and 3 h. It did not have any effect on brain HVA and 3-MT. 3. Ro 40-7592 was a broad spectrum COMT inhibitor decreasing striatal and hypothalamic 3-OMD (always to less than 30%), HVA (to less than 50%) and 3-MT levels (to less than 23%) significantly both at 1 and 3 h. It was more potent than OR-611. 4. CGP 28014 functioned as a weak COMT inhibitor in the periphery inhibiting 3-OMD formation only at 3 h. In contrast, it was fairly potent in decreasing the brain HVA and 3-MT levels at 1 h (to 37-22% and 42-35% in the striatum, and to 57-33% and 64-35% in the hypothalamus, respectively) but not at 3 h. Since CGP 28014, unlike OR-611 and Ro 40-7592, did not generally increase the brain DOPA, dopamine or DOPAC levels, it was not a typical COMT inhibitor.

Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats.

Effects of modified brain histamine contents on thyrotropin and prolactin secretion were studied in male rats. Under basal conditions the histamine content in the hypothalamus was approximately 8-10-fold higher than that in the striatum and the rest of the brain. L-histidine (1000 mg/kg, ip), a histamine precursor, and metoprine (20 mg/kg, ip), an inhibitor of histamine methyltransferase, elevated histamine content in the brain by 65% and 167%, respectively. When the treatments were given together an additive effect (119-250% increase) on brain histamine was observed. Metoprine significantly decreased serum prolactin levels, while L-histidine had no effect. This effect of metoprine was not modified by treatment with L-histidine. Thus, metoprine has an inhibitory effect on prolactin secretion that is not related to elevated brain histamine contents. The increased brain histamine content after L-histidine treatment had no effect on prolactin secretion. Basal levels of serum thyrotropin were decreased by both L-histidine and metoprine, L-histidine being more potent. In rats treated with alpha-fluoromethylhistidine, an inhibitor of L-histidine decarboxylase, the cold-induced (rats kept for 60 min at +4 degrees C) thyrotropin secretion was increased while the stress-induced prolactin secretion was decreased. In these rats, metoprine did not affect thyrotropin release but blunted the prolactin response. In conclusion, endogenous histamine inhibits thyrotropin secretion but does not affect prolactin release. Owing to its other effects, metoprine is not suitable as a tool to elevate endogenous histamine contents in the brain, at least when the regulation of anterior pituitary hormone release is being studied.

Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain.

A new COMT inhibitor, nitecapone (OR-462) or clorgyline, a MAO-A inhibitor, was infused into the 3rd brain ventricle (i.c.v.) of conscious male rats. None of the enzyme inhibitors given alone alter hypothalamic or striatal levels of L-dopa, dopamine or their metabolites. Most of the rats were pretreated with levodopa/carbidopa (LD/CD, 15/30 mg kg-1 intraperitoneally). Now, the action of nitecapone is localized in the hypothalamus since homovanillic acid (HVA) is decreased there, not in the striatum. The levels of 3-O-methyldopa (3-OMD) are not changed in either brain region, suggesting a lack of the peripheral leakage of nitecapone. Clorgyline (3 and 10 micrograms rat-1) elevates hypothalamic and dopamine levels. Nitecapone and clorgyline decrease prolactin (PRL) levels below those reduced by LD/CD treatment.

Evidence for cholecystokininA receptors in bovine adrenal chromaffin cells.

We have studied a possible role of cholecystokinin (CCK) in regulating adrenal medullary function. Caerulein (10(-10)-10(-7) M), a CCK receptor agonist, increased formation of inositol phosphates in primary cultured bovine adrenal medullary (BAM) chromaffin cells in a concentration-dependent manner. The effect of caerulein was antagonized by devazepide, a selective CCKA-receptor antagonist, but not by L-365.260, a selective CCKB-receptor antagonist. These results suggest that BAM cells possess functional CCK receptors of the CCKA-subtype. Stimulation of these receptors with caerulein activates a signal transduction pathway via phospholipase C. CCK may regulate catecholamine release in BAM cells.

Studies on the site and mechanism of the inhibitory action of intracerebral histamine on the cold-stimulated thyrotropin secretion in male rats.

The locus of the inhibitory action of histamine on cold-stimulated TSH secretion was studied in male rats. Various histaminergic drugs were given either into the median eminence (ME), the third ventricle, the rostral and caudal part of anterior hypothalamus (rAH and cAH) or the posterior hypothalamus (PH) of conscious rats. When infused into ME, histamine (5 and 10 micrograms/rat) decreased and mepyramine (2.5 micrograms) increased the cold-stimulated TSH secretion while a larger dose of mepyramine (10 micrograms/rat), impromidine (0.05 and 0.1 microgram/rat), 2-pyridylethylamine (2-PEA; 5 and 10 micrograms/rat) and cimetidine (2.5 and 7.5 micrograms/rat) had no effect. The inhibitory action of histamine (5 micrograms/rat) was most marked 30 min after the infusion into ME and it remained significant for at least 50 min. Neither cimetidine (50 and 100 mg/kg i.p.) nor mepyramine (10 and 20 mg/kg i.p.) antagonized the inhibitory action of histamine (5 micrograms/rat) in ME. Histamine (10 micrograms/side) inhibited the cold-stimulated TSH secretion likewise when infused bilaterally either into rAH, cAH or PH. TSH secretion induced by exogenous TRH (100 ng i.p.) was also inhibited by histamine (1 microgram/rat) given into the third ventricle. In conclusion, histamine seems to have an inhibitory action on the cold-stimulated TSH secretion. This action is apparently mediated through areas close to the third ventricle. The mechanism of this action seems to be fairly non-specific, i.e. it is mediated through neither H1- nor H2-receptors.

Characterization of dynorphin-containing neurons on dissociated dentate gyrus cell cultures.

In the dentate gyrus, the synthesis of the opioid peptide, dynorphin, is modulated by a variety of stimuli. In order to elucidate the cellular and molecular mechanisms regulating the synthesis of dynorphin in the hippocampus, we have established a routine primary cell culture of dentate granule neurons and identified granule-like neurons by a characteristic marker, dynorphin, in these cultures. Cultures were prepared from 7-day-old rat pups and maintained in medium with 2% fetal bovine serum. These cultures contained approximately 20% neurons and survived for over 4 weeks. After 2 weeks in culture, neurons expressing dynorphin-A and its messenger RNA were detected using immunocytochemistry and in situ hybridization, respectively. In dentate cultures, enkephalin-, cholecystokinin-, neuropeptide Y- and substance P-positive cells were observed in addition to dynorphin-positive cells with immunocytochemistry. The results suggest that dentate gyrus cell cultures provide a valid in vitro model for studying molecular mechanisms regulating prodynorphin gene expression.

Cholinergic regulation of thyrotropin secretion in male rats.

The cold-stimulated thyrotropin (TSH) secretion in male rats was suppressed by muscarinic agonists, i.e. Oxa-22, McN-A-343 (an M1 agonist), oxotremorine (an M2 agonist) and methacholine (a quaternary compound). The inhibitory effect of Oxa-22 was antagonized by atropine, butylscopolamine and glycopyrrolate as well as by pirenzepine, an M1 antagonist and AF-DX 116, a new M2 antagonist. Various muscarinic antagonists were not active when given alone. Cytisine, a peripheral nicotinic agonist, was not active but nicotine significantly suppressed the cold-stimulated TSH secretion. Its effect was counteracted by mecamylamine but not by hexamethonium. The thyrotropin releasing hormone (TRH)-induced TSH secretion was not inhibited by Oxa-22, nicotine or methacholine. These results show that irrespective of the receptor subtype (muscarinic1 or muscarinic2, nicotinic), cholinergic activation inhibits the cold-stimulated TSH secretion. The results also suggest that this inhibitory effect is at the hypothalamic rather than the anterior pituitary level. The muscarinic action seems to occur outside the blood-brain barrier but the nicotinic action occurs inside this barrier.

Differential disappearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat.

Development and disappearance of tolerance to various effects of morphine was studied by comparing the effect of acute morphine at 6 h and at 92 h after cessation of a 5-day regimen with increasing doses of morphine. After the 6-h lag time, tolerance manifested to the thermal, locomotor depressant and hormonal (stimulation of growth hormone and prolactin secretion) effects of morphine. The hypokinetic effect of morphine was replaced by a hyperkinetic effect and increased locomotor activity was evident following the challenge dose of morphine. Tolerance disappeared in different ways during the 92-h lag time. Tolerance persisted (hypothermic and hypokinetic effect) or disappeared considerably (prolactin secretion) during the 92-h withdrawal period. Tolerance to some effects also faded completely, and in contrast, even sensitization to various effects of morphine (growth hormone secretion, hyperthermic effect) could be seen after the 92-h withdrawal period. In addition, the original hypokinetic effect of morphine was replaced by a hyperkinetic effect (i.e., enhanced locomotor activity), which was even stronger after the 92-h lag time. The observed dissociation, which has not been seen to such an extent before, may be due to the differential modulation of the subtypes of mu-opioid receptors or differences in the adaptive mechanisms, e.g. conditioning, in various brain areas. Faster recovery of tolerance to an inhibitory than to a stimulatory effect of morphine during the withdrawal period may partially explain the sensitization to some effects of morphine.

N-nitro-L-arginine attenuates development of tolerance to antinociceptive but not to hormonal effects of morphine.

The effect of N-nitro-L-arginine methyl ester on thyrotropin (TSH), growth hormone (GH) and prolactin levels in serum was studied after a single dose in male rats. The effect of repeated N-nitro-L-arginine methyl ester on the development of tolerance to the multiple effects of morphine was also examined. N-Nitro-L-arginine methyl ester (25 mg/kg i.p.) decreased cold-stimulated (rats were kept 30 min at +4 degrees C) TSH levels but did not alter basal TSH, GH or prolactin levels. Acute or repeated N-nitro-L-arginine methyl ester treatments were not antinociceptive alone, neither did they modify the effect of acute morphine. A 5-day treatment with increasing doses of morphine induced antinociceptive tolerance. This was attenuated by N-nitro-L-arginine methyl ester co-administration on the 3rd day, less so on the 5th day. Repeated morphine produced tolerance to the effect on TSH (decrease) and prolactin (increase) levels, but sensitization to the GH-elevating effect, measured after a 4-day delay. A 5-day treatment with N-nitro-L-arginine methyl ester did not modify the development of tolerance to the hormonal effects of morphine. In the case of TSH, it is difficult to draw a conclusion because the 5-day N-nitro-L-arginine methyl ester and morphine treatment generally decreased basal TSH levels. Sensitization to the hyperthermic effect of morphine occurred after a 4-day delay and this was not altered by N-nitro-L-arginine methyl ester. These results suggest that both nitric oxide-dependent and independent mechanisms are involved in the development of tolerance to the various effects of morphine.

Variation in tolerance to the antinociceptive, hormonal and thermal effects of morphine after a 5-day pre-treatment of male rats with increasing doses of morphine.

The manifestation of tolerance to the effects of morphine on nociception and the secretion of anterior pituitary hormones, and the correlation of hormonal effects to changes in body temperature and to hypothalamic monoamines were studied in male rats. Morphine (three times a day in increasing doses) or saline (control) were administered intraperitoneally during a 5-day treatment and either saline or morphine was administered as an acute challenge 92 h later. The influence of the thermal environment on the effect of morphine on the body temperature was also studied. The 5-day morphine regimen was sufficient for the development of tolerance to the antinociceptive effect of morphine. After a 92-h lag-time, the tolerance was still complete. Tolerance to the depressant effect of morphine (10-25 mg/kg) on cold-stimulated TSH secretion was seen at 2 h, but was only barely detectable at 1 h, after the injection of a challenge dose. On the other hand, a tolerance to the stimulatory effect of morphine on prolactin secretion was already seen 1 h after the acute dose of morphine. Tolerance to the hypothermic effect of morphine (25 mg/kg) was evident in rats kept at +4 degrees C after the challenge dose. On the contrary, no tolerance to the hyperthermic effect of morphine (15 or 25 mg/kg) was observed in rats kept at +30 degrees C. However, the hyperthermia was reversed when these rats were moved to +4 degrees C for 30 min, irrespective of whether they were morphine pretreated or not. Thus the removal of the hyperthermic stimulus decreased the core temperature of all rats.(ABSTRACT TRUNCATED AT 250 WORDS)

[Effect of Catechol-O-methyltransferase deficiency on reinforcing effects of cocaine (experimental study)].

Catechol-O-methyltransferase (COMT) remains an important regulatory element in prefrontal cortex dopamine homeostasis. The literature data suggest that individual differences in COMT activity (Val158Met polymorphism) might have indirect downstream effects on the reward system. The aim of the present study was to examine whether COMT deletion affects reinforcing effects of cocaine in mice. The study was conducted in male mice with homozygous COMT deletion as well as their C57BL/6J wild-type littermates. Animals were trained to nose-poke to receive response-contingent intravenous infusions of cocaine (0.3 mg/kg per infusion; final schedule of reinforcement - fixed ratio (FR) 3 time out 30 s). Following the initial acquisition phase, cocaine self-administration dose-effect functions (0.03, 0.1, 0.3, 1, and 3 mg/kg per infusion) were determined under FR3 and progressive ratio (PR) schedules of reinforcement. Cocaine dose-dependently maintained responding under FR3 and PR schedule of reinforcement when the unit dose of cocaine was varied across the sessions. The total cocaine intake did not differ in COMT deletion mice and wild-type mice. The results of this study suggest that individual differences in COMT activity do not affect primary reinforcing effects of cocaine in mice.

Medium-throughput computer aided micro-island method to assay embryonic dopaminergic neuron cultures in vitro.

In Parkinson's disease (PD) midbrain dopaminergic (DA) neurons degenerate and die, causing loss of motor function. Currently no therapies exist to ameliorate neurodegeneration or to restore DA neurons, although neurotrophic factors (NTFs) are promising leads. Prior in vivo studies the NTFs are routinely assessed in vitro by quantifying the survival of DA neurons from embryonic rodent midbrain cultures. Current in vitro methods are limited in terms of assay reliability, arduous workflow, low throughput, low statistical power and may obscure detection of molecules with minor yet critically important therapeutic effects. We have developed a medium-throughput, micro-island culture method. It permits analysis of 10-12 data points from a single embryo - several fold more than any previously published method - and enables comparisons of DA neurons from a single gene knockout (KO) embryo. It is computer-aided, improves statistical power and decreases the number of animals and workload per experiment. This method enhances testing capabilities of NTFs and other factors, and enables small scale screening of chemical drug libraries. We have validated the method by confirming the known effects of glial cell line-derived neurotrophic factor (GDNF) and neurturin (NRTN), and demonstrated additive effects via simultaneous addition of GDNF and heparin binding growth associated molecule (HB-GAM). We also show for the first time that DA neurons isolated from GDNF receptor RET-deficient mice are still GDNF responsive, suggesting the presence of an alternative non-RET receptor for GDNF in the DA system. Finally, the method can be adapted for analyses of other low abundance neuronal systems.

Attempts to antagonize the effect of histamine on the cold-stimulated thyrotropin secretion in male rats.

Histamine given directly into the 3rd ventricle inhibits the enhancement of thyrotropin secretion induced by cold-exposure (4 degrees, 30 min.) in male rats. This effect was antagonized neither by mepyramine, a H1-receptor antagonist, nor by cimetidine, a H2-receptor antagonist. Histamine would not have an indirect mechanism of action through adrenergic alpha 1- or alpha 2-receptors in rat hypothalamus, since pretreatment with neither phenoxybenzamine nor yohimbine had any effect on histamine suppressed TSH cold-response. Further, it was also tested if histamine could decrease the TSH secretion through cholinergic-, GABA-, serotonergic- or dopaminergic receptors but no results supporting such a mechanism of action were obtained. The effect of histamine was not modified by pretreatment with naloxone or desipramine either. Imidazole acetic acid, IAA, a metabolite of histamine, had no effect on cold-induced TSH secretion. It is concluded that the effect of exogenous histamine on cold-stimulated TSH secretion is not mediated through H1- or H2-receptors. Histamine may decrease brain noradrenergic activity which is important in the generation of TSH cold-response. In addition, the effect of exogenous histamine might be due to decreased endogenous histaminergic activity in rat brain.